IAXO-102
Based on 6 publication(s) in Google Scholar
IAXO-102 is a TLR4 antagonist which negatively regulates TLR4 signalling. IAXO-102 inhibits MAPK and p65 NF-κB phosphorylation and expression of TLR4 dependent proinflammatory protein. IAXO-102 also prevents experimental abdominal aortic aneurysm development.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 98.0%
- CAS 番号: 1115270-63-7
- 分子式: C35H71NO5
- 分子量:585.94
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
MedChemExpress（MCE）の使用を引用している文献 IAXO-102
More
生物活性
製品説明
IC50 & Target
[1]|
TLR4 |
体外実験
IAXO-102 (1-10 μM, for 2 hours) inhibits MAPK and p65 NF-κB phosphorylation in human umbilical vein endothelial (HUVEC) cells[1].
?
IAXO-102 (10 μM, for 17 hours) suppresses LPS induced proinflammatory proteins MCP-1 and IL-8 production in HUVEC[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human umbilical vein endothelial (HUVEC) cells
-
Concentration:1-10 µM
-
Incubation Time:Pretreatment for 1 hour and then exposed to LPS (100 ng/mL) for additional 1 hour
-
Result:Significantly inhibited LPS-stimulated MAPK/p65nF-ΚB phosphorylation.
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Six-monthold ApoE−/−/C57Bl6[1]
-
Dosage:3 mg/kg/day
-
Administration:S.C. for 28 days
-
Result:Significantly retarded Angiotensin II-induced increase in aortic diameter.
化学情報
-
CAS 番号 1115270-63-7
-
性状 Solid
-
分子量 585.94
-
分子式 C35H71NO5
-
Color White to off-white
-
SMILES
CCCCCCCCCCCCCCO[C@@H]1[C@H]([C@@H]([C@@H](CN)O[C@@H]1OC)O)OCCCCCCCCCCCCCC
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
Microbiota-indole-3-propionic acid-heart axis mediates the protection of leflunomide against αPD1-induced cardiotoxicity in mice. [Abstract]2025 Mar 19;16(1):2651. PMID: 40108157 -
Redox Biol
Deficiency of S100 calcium binding protein A9 attenuates vascular dysfunction in aged mice. [Abstract]2023 Jul:63:102721. PMID: 37163872 -
-
Mol Med Rep
All‑trans retinoic acid promotes macrophage phagocytosis and decreases inflammation via inhibiting CD14/TLR4 in acute lung injury. [Abstract]2021 Dec;24(6):868. PMID: 34676874 -
Cancer Chemother Pharmacol
Effects of a novel toll-like receptor 4 antagonist IAXO-102 in a murine model of chemotherapy-induced gastrointestinal toxicity. [Abstract]2022 Sep;90(3):267-278. PMID: 35962138 -
溶剤 & 溶解度
体外:
Ethanol : 50 mg/mL (85.33 mM; Need ultrasonic)
DMSO : 3.33 mg/mL (5.68 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
体内:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 0.83 mg/mL (1.42 mM); Clear solution
This protocol yields a clear solution of ≥ 0.83 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (8.3 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% EtOH 90% Corn Oil
Solubility: ≥ 0.83 mg/mL (1.42 mM); Clear solution
This protocol yields a clear solution of ≥ 0.83 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (8.3 mg/mL) to 900 μL Corn oil, and mix evenly.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (272 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
取扱説明書 (2659 KB)
参考文献
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / Ethanol | 1 mM | 1.7067 mL | 8.5333 mL | 17.0666 mL | 42.6665 mL |
| 5 mM | 0.3413 mL | 1.7067 mL | 3.4133 mL | 8.5333 mL | |
| Ethanol | 10 mM | 0.1707 mL | 0.8533 mL | 1.7067 mL | 4.2666 mL |
| 15 mM | 0.1138 mL | 0.5689 mL | 1.1378 mL | 2.8444 mL | |
| 20 mM | 0.0853 mL | 0.4267 mL | 0.8533 mL | 2.1333 mL | |
| 25 mM | 0.0683 mL | 0.3413 mL | 0.6827 mL | 1.7067 mL | |
| 30 mM | 0.0569 mL | 0.2844 mL | 0.5689 mL | 1.4222 mL | |
| 40 mM | 0.0427 mL | 0.2133 mL | 0.4267 mL | 1.0667 mL | |
| 50 mM | 0.0341 mL | 0.1707 mL | 0.3413 mL | 0.8533 mL | |
| 60 mM | 0.0284 mL | 0.1422 mL | 0.2844 mL | 0.7111 mL | |
| 80 mM | 0.0213 mL | 0.1067 mL | 0.2133 mL | 0.5333 mL |
IAXO-102 関連分類
HY-125171 関連分類
Powered by Bioz